Human Genome Editing: Who Gets to Decide?
By Dietram A. Scheufele and David Beier,
Scientific American
| 05. 18. 2017
A report from the National Academies says scientists alone can't make the call—they must engage with the broader public
Meaningful public debate seems almost impossible in an era of political bubbles isolating us one from another and facts becoming a matter of opinion. Unfortunately, our political culture is crumbling just as rapid scientific breakthroughs confront us with some of the most serious moral, ethical and policy questions of our age.
And there is a real urgency. Scientific breakthroughs surrounding human gene editing, for instance, have moved medical treatments that seemed science fiction just a few years ago within scientists’ reach. Today, tools like CRISPR/Cas9 allow making modifications to the human genome in ways that are more efficient and safer than ever before. And the science emerges rapidly, constantly offering new venues for treating what used to be incurable diseases.
The idea of editing the human genome raises questions that science alone cannot answer. What are the ethical and moral boundaries of the human race editing its own genome? Who will have access to many of the potentially expensive medical treatments...
Related Articles
By Rob Stein, NPR [cites CGS' Katie Hasson] | 08.06.2025
A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies.
His work was reviled as reckless and unethical because, among other reasons, gene-editing was so new...
By Susanna Smith, Genetic Frontiers | 07.28.2025
Key Topics
How does the American far right view genetics and genetic technologies?
What is the history of the American cultural pursuit of trying to choose smarter children? What has science shown us about the relationship of heredity and intelligence...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...